In a letter submitted to the House Energy and Commerce Subcommittee on Oversight and Investigations for a hearing on challenges implementing value-based and alternative payment models under the Medicare Access and CHIP Reauthorization Act of 2015, AHA encouraged certain statutory and regulatory policies to advance and flexibly implement these models. Recommendations include extending incentive payments; investing in resources and infrastructure to support rural hospitals’ transition to APMs; improving cost measures in the Merit-based Incentive Payment System; and supporting more gradual transitions to risk for certain Medicare Shared Savings Program accountable care organizations.  
 
“One additional factor that has impacted the transition to value-based care has been the longstanding challenges with insufficient reimbursement,” AHA said, including site-neutral payment cuts that have contributed to Medicare’s “chronic failure to cover the cost of caring for its beneficiaries.” The association said it “strongly opposes additional site-neutral payment cuts, which threaten access to care.”  

Related News Articles

Headline
The Centers for Medicare & Medicaid Services is launching a new initiative for state Medicaid programs to purchase prescription drugs at prices aligned…
Headline
All 50 states have applied for the Rural Health Transformation Program, the Centers for Medicare & Medicaid Services announced Nov. 5. The program will…
Headline
Bill Gassen, Sanford Health president and CEO and AHA chair-elect designate, and Deb Koski, Sanford Health chief philanthropy officer, discuss how a strong…
Headline
The AHA commented Nov. 3 on the Centers for Medicare & Medicaid Services’ calendar year 2026 final rule for the physician fee schedule. The rule, released…
Headline
The Centers for Medicare & Medicaid Services Oct. 31 released its calendar year 2026 final rule for the physician fee schedule. As required by law,…
Headline
The Health Resources and Services Administration posted on its website that it had approved eight drug company plans for participation in the 340B Rebate Model…